MCID: PLY020
MIFTS: 45

Polyradiculoneuropathy malady

Category: Neuronal diseases

Aliases & Classifications for Polyradiculoneuropathy

About this section

Aliases & Descriptions for Polyradiculoneuropathy:

Name: Polyradiculoneuropathy 11 50 39 13 68

Classifications:



External Ids:

Disease Ontology11 DOID:4308
SNOMED-CT62 128078004
MeSH39 D011129

Summaries for Polyradiculoneuropathy

About this section
Wikipedia:71 Polyradiculoneuropathy describes a condition in which polyneuropathy and polyradiculopathy occur... more...

MalaCards based summary: Polyradiculoneuropathy is related to chronic inflammatory demyelinating polyradiculoneuropathy and polyradiculoneuropathy associated with igg/iga/igm monoclonal gammopathy without known antibodies. An important gene associated with Polyradiculoneuropathy is PMP22 (Peripheral Myelin Protein 22), and among its related pathways are Neural Crest Differentiation and Th17 Differentiation Pathway. Affiliated tissues include t cells, spinal cord and brain, and related mouse phenotypes are muscle and normal.

Related Diseases for Polyradiculoneuropathy

About this section

Diseases related to Polyradiculoneuropathy via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50)    (show all 192)
idRelated DiseaseScoreTop Affiliating Genes
1chronic inflammatory demyelinating polyradiculoneuropathy12.1
2polyradiculoneuropathy associated with igg/iga/igm monoclonal gammopathy without known antibodies11.8
3chronic inflammatory demyelinating polyneuropathy11.5
4neuropathy, inflammatory demyelinating11.1
5guillain-barre syndrome11.1
6chronic inflammatory demyelinating polyneuritis10.9
7subacute inflammatory demyelinating polyneuropathy10.9
8chronic polyradiculoneuritis10.8
9hereditary type 2 neuropathy10.3MPZ, PMP22
10chrna1-related congenital myasthenic syndrome10.3MPZ, PMP22
11surfactant metabolism dysfunction, pulmonary, 210.3MPZ, PMP22
12hypertonia10.3MPZ, PMP22
13pneumonic plague10.3MPZ, PMP22
14craniorachischisis10.3MBP, MPZ, PMP22
15deafness, autosomal recessive 7610.2MPZ, PMP22
16charcot-marie-tooth disease, type 1e10.2MBP, MPZ, PMP22
17mohr-tranebjaerg syndrome10.2MBP, MPZ, PMP22
18asymptomatic neurosyphilis10.2IFNG, IL10
19classic galactosemia and clinical variant galactosemia10.2MPZ, PMP22
20korsakoff's amnesic syndrome10.2MBP, MPZ, PMP22
21uterine ligament serous adenocarcinoma10.2ALB, MPZ, PMP22
22nguyen syndrome10.2IL10, IL17A
23white piedra10.2MBP, MPZ, PMP22
24ciliary discoordination, due to random ciliary orientation10.2ALB, IFNG, IL10
25rosacea10.2ALB, IFNG, IL10
26hereditary alpha tryptasemia syndrome10.2ALB, IFNG, IL10
27subungual glomus tumor10.2IFNG, TBX21
28parkinson disease 1110.2IFNG, IL10, IL17A
29plummer's disease10.2ALB, IFNG, IL10
30denys-drash syndrome10.2IFNG, IL10, IL17A
31orbital osteomyelitis10.2IFNG, IL10, IL17A
32loiasis10.2IFNG, IL10, IL17A
33depressed scar10.2ALB, IFNG, IL10
34disease of mental health10.2IFNG, IL10, IL17A
35trichomalacia10.2IL10, IL17A, MBP
36gastric dilatation10.2IL10, IL17A, MBP
37paratyphoid fever10.2ALB, IFNG, IL10
38follicular adenoma10.2IFNG, IL10, IL17A
39motor peripheral neuropathy10.2IFNG, IL10, IL17A
40anterior foramen magnum meningioma10.2ALB, IFNG, IL10
41liver inflammatory pseudotumor10.2ALB, IFNG, IL10
42burns10.1IFNG, IL10, IL17A
43balkan nephropathy10.1IFNG, IL10, IL17A
44uterus interstitial leiomyoma10.1ALB, IFNG, IL10
45neonatal stroke10.1IFNG, IL10, MBP
46parasitic protozoa infectious disease10.1IFNG, IL10, IL17A
47sclerosing adenosis of breast10.1ALB, IFNG, IL10
48severe combined immunodeficiency, t cell-negative, b-cell/natural killer-cell positive10.1IFNG, IL10
49chronic gonorrhea of cervix10.1IFNG, IL10, IL17A
50benign eccrine breast spiradenoma10.1IFNG, IL10, STAT3

Graphical network of the top 20 diseases related to Polyradiculoneuropathy:



Diseases related to polyradiculoneuropathy

Symptoms & Phenotypes for Polyradiculoneuropathy

About this section

MGI Mouse Phenotypes related to Polyradiculoneuropathy according to GeneCards Suite gene sharing:

41 (show all 13)
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:00053699.1ALB, CXCR4, IFNG, IL10, PMP22, STAT3
2MP:00028738.7ALB, IFNB1, IFNG, IL10, MBP, PRF1
3MP:00053818.5ALB, CXCR4, IFNG, IL10, IL17A, STAT3
4MP:00053898.4CXCR4, IFNG, IL10, MBP, MPZ, PMP22
5MP:00053798.2ALB, CXCR4, IFNG, IL10, IL17A, PRF1
6MP:00053888.0CXCR4, IFNG, IL10, IL17A, STAT3, TBX21
7MP:00020067.9ALB, CXCR4, IFNB1, IFNG, IL10, PRF1
8MP:00107687.9ALB, CXCR4, IFNG, IL10, IL17A, MBP
9MP:00053847.7ALB, CXCR4, IFNG, IL10, MBP, MPZ
10MP:00036317.0CXCR4, IFNB1, IFNG, IL10, MBP, MPZ
11MP:00053766.6ALB, CXCR4, IFNB1, IFNG, IL10, IL17A
12MP:00053976.6CCL5, CXCR4, IFNB1, IFNG, IL10, IL17A
13MP:00053876.6CCL5, CXCR4, IFNB1, IFNG, IL10, IL17A

Drugs & Therapeutics for Polyradiculoneuropathy

About this section

Drugs for Polyradiculoneuropathy (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 49)
idNameStatusPhaseClinical TrialsCas NumberPubChem Id
1Rho(D) Immune GlobulinPhase 4, Phase 3, Phase 2326
2Immunoglobulins, IntravenousPhase 4, Phase 3, Phase 2333
3AntibodiesPhase 4, Phase 3, Phase 26394
4ImmunoglobulinsPhase 4, Phase 3, Phase 26394
5gamma-GlobulinsPhase 4, Phase 3, Phase 2326
6
Prednisoneapproved, vet_approvedPhase 3139853-03-25865
Synonyms:
(1S,2R,10S,11S,14R,15S)-14-hydroxy-14-(2-hydroxyacetyl)-2,15-dimethyltetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadeca-3,6-diene-5,17-dione
(8S,9S,10R,13S,14S,17R)-17-hydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-6,7,8,9,12,14,15,16-octahydrocyclopenta[a]phenanthrene-3,11-dione
(8xi,9xi,14xi)-17,21-dihydroxypregna-1,4-diene-3,11,20-trione
.delta. E
.delta.(sup1)-Cortisone
.delta.-Cortelan
.delta.-Cortisone
.delta.-Cortone
.delta.-E
.delta.1-Cortisone
.delta.1-Dehydrocortisone
.delta.sone
1,2-Dehydrocortisone
1,4-Pregnadiene-17-alpha,21-diol-3,11,20-trione
1,4-Pregnadiene-17.alpha.,21-diol-3,11,20-trione
1,4-Pregnadiene-17alpha,21-diol-3,11,20-trione
1-Cortisone
1-Dehydrocortisone
17,21-Dihydroxypregna-1,4-diene-3,11,20-trione
17alpha,21-Dihydroxy-1,4-pregnadiene-3,11,20-trione
53-03-2
68-59-7
81552_FLUKA
AC-11112
AC1L1LB2
AC1Q29EZ
ACon0_000082
ACon1_000297
AI3-52939
Adasone
Ancortone
Apo-Prednisone
Apo-prednisone
BPBio1_000323
BRD-K85883481-001-04-2
BSPBio_000293
Betapar
Bicortone
Bio-0649
C07370
C21H26O5
CCRIS 2646
CHEBI:8382
CHEMBL635
CID5865
CPD001227202
Cartancyl
Colisone
Cortan
Cortancyl
Cortidelt
Cotone
DB00635
Dacorten
Dacortin
Decortancyl
Decortin
Decortisyl
Dehydrocortisone
Dekortin
Delcortin
Dellacort
Dellacort A
Delta Cortelan
Delta E
Delta E.
Delta-Cortelan
Delta-Dome
Delta-cortelan
Delta-cortisone
Delta-cortone
Delta-dome
Deltacortene
Deltacortisone
Deltacortone
Deltasone
Deltasone, Liquid Pred, Orasone, Adasone, Deltacortisone,Prednisone
Deltison
Deltisona
Deltisone
Deltra
Di-Adreson
Diadreson
EINECS 200-160-3
Econosone
Encorton
Encortone
Enkortolon
Enkorton
Fernisone
Fiasone
HMS1568O15
HMS2090J13
HSDB 3168
Hostacortin
In-Sone
Incocortyl
 
Juvason
Kortancyl
LMST02030180
LS-1325
Liquid Pred
Lisacort
Lodotra
MEGxm0_000443
MLS001061265
MLS001304073
MLS001335907
MLS001335908
MLS002154191
MLS002207083
Me-Korti
Metacortandracin
Meticorten
Meticorten (Veterinary)
Metrevet (Veterinary)
MolPort-001-740-041
NCGC00090766-01
NCGC00090766-02
NCGC00090766-03
NCI-C04897
NCI60_000008
NSC 10023
NSC10023
Nisona
Nizon
Novoprednisone
Nurison
Orasone
Origen Prednisone
P1276
P6254_SIGMA
PRD
Panafcort
Panasol
Paracort
Parmenison
Pehacort
Precort
Predeltin
Prednicen-M
Prednicorm
Prednicort
Prednicot
Prednidib
Prednilonga
Prednison
Prednisona
Prednisona [INN-Spanish]
Prednisone
Prednisone Intensol
Prednisone [INN:BAN]
Prednisonum
Prednisonum [INN-Latin]
Prednitone
Prednizon
Prednovister
Presone
Prestwick0_000077
Prestwick1_000077
Prestwick2_000077
Prestwick3_000077
Prestwick_405
Pronison
Pronisone
Rectodelt
Retrocortine
S1622_Selleck
SAM002264641
SK-Prednisone
SMR000718760
SMR001227202
SPBio_002214
Servisone
Sone
Sterapred
Supercortil
U 6020
UNII-VB0R961HZT
Ultracorten
Ultracortene
WLN: L E5 B666 CV OV AHTTT&J A1 E1 FV1Q FQ
Winpred
Wojtab
ZINC03875357
Zenadrid
Zenadrid (veterinary)
Zenadrid [veterinary]
delta cortelan
delta(sup 1)-Cortisone
delta(sup 1)-Dehydrocortisone
delta-1-Cortisone
delta-1-Dehydrocortisone
delta-Cortisone
delta-Cortone
7
Mycophenolate mofetilapproved, investigationalPhase 3952128794-94-55281078
Synonyms:
115007-34-6
128794-94-5
140401-05-4
2-Morpholinoethyl (4E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-5-phthalanyl)-4-methyl-4-hexenoate
2-Morpholinoethyl (E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-5-phthalanyl)-4-methyl-4-hexenoate
2-Morpholinoethyl (e)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-5-phthalanyl)-4-methyl-4-hexenoate
2-morpholin-4-ylethyl (4E)-6-[4-hydroxy-7-methyl-6-(methyloxy)-3-oxo-1,3-dihydro-2-benzofuran-5-yl]-4-methylhex-4-enoate
2-morpholin-4-ylethyl (E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1H-2-benzofuran-5-yl)-4-methylhex-4-enoate
4-Hexenoic acid, 6-(1,3-dihydro-4-hydroxy-6-methoxy-7-methyl -3-oxo-5-isobenzofuranyl)-4-methyl-, 2-(4-morpholinyl)ethyl ester, (4E)
AC-1562
AC1NQXZW
AC1Q6O6X
AR-1J6939
BB_NC-2566
C07908
C23H31NO7
CHEMBL1456
CID5281078
CellCept
CellCept, RS 61443, TM-MMF, Mycophenolate mofetil
Cellcept
Cellcept (TN)
D00752
DB00688
HMS2090A03
 
HSDB 7436
I01-0898
I06-1947
LS-172272
LS-75572
ME-MPA
MMF
MMF CellCept(TM)
MolPort-000-883-800
Munoloc
Mycophenolate mofetil (JAN/USAN)
Mycophenolic acid morpholinoethyl ester
Mycophenylate mofetil
NCGC00159459-02
NCGC00159459-03
NSC724229
R-99
RS 61443
RS-61443
RS-61443-190
S1501_Selleck
TL8000648
TM-MMF
UNII-9242ECW6R0
ZINC21297660
mycophenolate mofetil
8
Mycophenolic acidapprovedPhase 395224280-93-1446541
Synonyms:
(e)-6-(4-Hydroxy-6-methoxy-7-methyl-3-oxo-5-phthalanyl)-4-methyl-4-hexenoic acid
Acide mycophenolique
Acido micofenolico
Acidum mycophenolicum
 
Melbex
Micofenolico acido
Mycophenoic acid
Mycophenolate
Mycophenolsäure
Myfortic
9
Glycineapproved, nutraceutical, vet_approvedPhase 323256-40-6750
Synonyms:
(1-13c)glycinato
(15N)Glycine
15527_RIEDEL
15527_SIAL
15743-44-9 (mono-potassium salt)
17829-66-2 (cobalt salt)
18875-39-3
2,2-dialkylglycines
2-Aminoacetate
2-Aminoacetic acid
2311-65-1
25718-94-9
29728-27-6 (monoammonium salt)
32817-15-5 (copper salt)
33226_RIEDEL
33226_SIAL
33242-26-1 (calcium salt)
35947-07-0 (calcium salt (2:1))
410225_SIAL
50046_FLUKA
50046_SIGMA
513-29-1 (sulfate (3:1))
52955-63-2
56-40-6
57678-19-0
6000-43-7 (hydrochloride)
6000-44-8 (mono-hydrochloride salt)
63183-41-5 (hydrochloride hydrogen carbonate)
71295-98-2 (phosphate (1:1))
7490-95-1 (hydrochloride (2:1)
7490-95-1 (hydrochloride (2:1))
7575-55-5
848646-45-7
87867-94-5
AB-131/40217813
AB1002628
AC1L19XW
AC1Q28JW
AC1Q53O0
AI3-04085
AKOS000119626
AMINOACETIC ACID 1.5% IN PLASTIC CONTAINER
AR-1A0345
AR-1A0532
Acide aminoacetique
Acide aminoacetique [INN-French]
Acido aminoacetico
Acido aminoacetico [INN-Spanish]
Acidum aminoaceticum
Acidum aminoaceticum [INN-Latin]
Aciport
Amino-Acetate
Amino-Acetic acid
Aminoacetate
Aminoacetic acid
Aminoazijnzuur
Aminoessigsaeure
Aminoethanoate
Aminoethanoic acid
Amitone
B72BA06C-60E9-4A83-A24A-A2D7F465BB65
BPBio1_001222
Biomol-NT_000195
C00037
CCRIS 5915
CHEBI:15428
CHEBI:15705
CHEBI:16228
CHEMBL773
CID750
CPD-8569
Corilin
D00011
DB00145
EINECS 200-272-2
 
FEMA No. 3287
FT-0083159
G
G0099
G0317
G5417_SIGMA
G5523_SIGMA
G7126_SIGMA
G7403_SIGMA
G8790_SIGMA
G8898_SIGMA
GLY (IUPAC abbrev)
GLYCINE 1.5% IN PLASTIC CONTAINER
GLYCINE, ACS
Glicina
Glicina [INN-Spanish]
Glicoamin
Gly
Glycin
Glycine
Glycine (JP15/USP)
Glycine [INN]
Glycine iron sulphate (1:1)
Glycine, homopolymer (VAN)
Glycine, labeled with carbon-14
Glycine, non-medical
Glycine-UL-14C hydrochloride
Glycinum
Glycinum [INN-Latin]
Glycocoll
Glycolixir
Glycosthene
Glykokoll
Glyzin
Gyn-Hydralin
Gyn-hydralin
H-Gly-OH
H2N-CH2-COOH
HSDB 495
Hampshire glycine
Hgly
InChI=1/C2H5NO2/c3-1-2(4)5/h1,3H2,(H,4,5
KST-1A2919
KST-1A8102
L-Glycine
L-alpha-amino acids
L001246
LS-218
Leimzucker
MolPort-000-871-607
NCGC00024503-01
NCGC00024503-02
NChemBio.2007.13-comp1
NSC 25936
NSC25936
P8791_SIGMA
Padil
Polyglycine II
S04-0135
Sucre de gelatine
Tocris-0219
UNII-TE7660XO1C
W328707_ALDRICH
WLN: Z1VQ
aminoacetic acid
an alpha amino acid ester
bmse000089
gly
glycine
nchem.554-comp2
nchembio.121-comp9
nchembio.145-comp33
nchembio.198-comp12
nchembio.265-comp9
nchembio.266-comp30
polyglycine
10Hormone AntagonistsPhase 3, Phase 213180
11HormonesPhase 3, Phase 214415
12glucocorticoidsPhase 35103
13Hormones, Hormone Substitutes, and Hormone AntagonistsPhase 3, Phase 213168
143,4-diaminopyridinePhase 320
15Antineoplastic Agents, HormonalPhase 35592
16Fingolimod HydrochloridePhase 388
17Potassium Channel BlockersPhase 3, Phase 2180
18Immunosuppressive AgentsPhase 3, Phase 213086
19Immunoglobulin GPhase 3275
20Anti-Inflammatory AgentsPhase 310729
21Pharmaceutical SolutionsPhase 3, Phase 28192
22Antibiotics, AntitubercularPhase 37180
23Anti-Bacterial AgentsPhase 311226
24
Interferon beta-1aapproved, investigationalPhase 2200145258-61-36438354
Synonyms:
145258-61-3
Avonex
Avonex (TN)
Belerofon
D04554
 
Fibroblast interferon
IFN-beta
Interferon beta precursor
Interferon beta-1a
Interferon beta-1a (USAN)
Interferon beta-1a (genetical recombination)
Interferon beta-1a (genetical recombination) (JAN)
25
4-AminopyridineapprovedPhase 269504-24-51727
Synonyms:
.gamma.-Aminopyridine
275875_ALDRICH
36687_FLUKA
36687_RIEDEL
4 AP
4 Aminopyridine
4 Aminopyridine Sustained Release
4-AP
4-Aminopyridine
4-Aminopyridine 10
4-Aminopyridine Sustained Release
4-Pyridinamine
4-Pyridylamine
4-aminopyridine
5-22-09-00106 (Beilstein Handbook Reference)
504-24-5
A 0152
A0414
A78403_ALDRICH
AB1004971
AC-907/25014071
AC1L1C3R
AC1Q52BM
AI3-52547
AKOS000119896
Amaya
Amino-4 pyridine
Amino-4-Pyridine
Ampydin
Ampyra
Avitrol
Avitrol 200
BB_SC-6974
BRN 0105782
BSPBio_001562
Bio1_000353
Bio1_000842
Bio1_001331
Bio2_000282
Bio2_000762
C13728
C5H6N2
CHEBI:34385
CHEMBL284348
CID1727
Caswell No. 038
Compound 1861
D015761
D04127
Dalfampridine
DivK1c_000572
EINECS 207-987-9
EL-970
EPA Pesticide Chemical Code 069201
EU-0100032
FT-0083754
Fampridina
Fampridine
Fampridine (USAN/INN)
Fampridine SR
Fampridine [USAN:INN]
Fampridine-PR
Fampridine-SR
Fampridinum
HC150041
HMS1361O04
HMS1791O04
HMS1921H15
HMS1989O04
HMS2092F05
HMS501M14
HSDB 6037
IDI1_000572
IDI1_034032
InChI=1/C5H6N2/c6-5-1-3-7-4-2-5/h1-4H,(H2,6,7
KBio1_000572
 
KBio2_000282
KBio2_000635
KBio2_002850
KBio2_003203
KBio2_005418
KBio2_005771
KBio3_000563
KBio3_000564
KBio3_001888
KBioGR_000282
KBioGR_001505
KBioSS_000282
KBioSS_000635
LS-130202
Lopac-A-0152
Lopac0_000032
MLS000069400
Mi-W-3
MolPort-000-146-022
N07XX07
NCGC00015009-01
NCGC00015009-03
NCGC00015009-12
NCGC00024890-01
NCGC00024890-02
NCGC00024890-03
NCGC00024890-04
NCGC00024890-05
NCGC00024890-06
NCGC00024890-07
NCGC00024890-08
NCGC00024890-09
NCGC00024890-10
NINDS_000572
NSC 15041
NSC15041
Neurelan
Neurelan (TN)
P-Aminopyridine
PYRIDINE,4-AMINO
Philips 1861
Phillips 1861
Pimadin (free base)
Prc 1237
Pymadin
Pymadine
RCRA waste no. P008
SDCCGMLS-0066228.P001
SMR000058211
SPBio_001486
SPECTRUM1501130
STK298717
Spectrum2_001413
Spectrum3_000914
Spectrum4_001013
Spectrum5_001501
Spectrum_000155
Sustained Release, 4-Aminopyridine
TL8003344
Tocris-0940
UNII-BH3B64OKL9
UPCMLD-DP125
UPCMLD-DP125:001
VMI 10-3
VMI 103
VMI-10-3
VMI-103
VMI103
WLN: T6NJ DZ
[J.Pharmacol.Exp.Ther. 275:864 (1995)]
gamma-Aminopyridine
nchem.892-comp4
p-Aminopyridine
p-Aminopyridine [UN2671] [Poison]
p-Aminopyridine [UN2671] [Poison]
pyridin-4-amine
pyridin-4-ylamine
26
Folic Acidapproved, nutraceutical, vet_approvedPhase 2439259-30-36037
Synonyms:
(2S)-2-[[4-[(2-amino-4-oxo-1H-pteridin-6-yl)methylamino]benzoyl]amino]pentanedioic acid
01769_FLUKA
2d0k
33609-88-0
36653-55-1 (mono-potassium salt)
59-30-3
6484-89-5 (mono-hydrochloride salt)
AC-11682
AC1L1LNX
AI3-26387
AKOS000503224
ARONIS014410
Acfol (Spain)
Acide folique
Acide folique [INN-French]
Acido folico
Acido folico [INN-Spanish]
Acidum folicum
Acidum folicum [INN-Latin]
Acifolic
Antianemia factor
Apo-Folic
BIDD:ER0563
BIDD:GT0641
BIF0608
BPBio1_000654
BSPBio_000594
BSPBio_002338
C00504
C20H20N6O6
CAS-59-30-3
CCRIS 666
CHEBI:27470
CHEMBL1622
CID6037
CPD000471860
Cytofol
D00070
DB00158
DivK1c_000494
Dosfolat B activ
EINECS 200-419-0
F0043
F7876_SIAL
F7876_SIGMA
F8758_SIGMA
F8798_SIAL
F8890_SIGMA
FOL
Facid
Factor U
Folacid
Folacin
Folaemin
Folaemin [Netherlands]
Folan
Folasic (Australia)
Folate
Folbal
Folcidin
Folcidin (VAN)
Folcysteine
Foldine
Foldine [France]
Folettes
Foliamin
Folic
Folic acid
Folic acid (JP15/USP/INN)
Folic acid (TN)
Folic acid [BAN:INN:JAN]
Folic acid [INN:BAN:JAN]
Folic acid dihydrate
Folicet
Folicet (TN)
Folico
Folico (Italy)
Folina
Folina (Italy)
Folipac
Folsaeure
 
Folsan
Folsaure
Folsav
Folvite
Folvron
Glutamic acid, N-(p-(((2-amino-4-hydroxypyrimido(4,5-b)pyrazin-6-yl)methyl)amino)benzoyl)-, L
HMS1921D20
HMS2092N17
HMS501I16
HSDB 2002
IDI1_000494
InChI=1/C19H19N7O6/c20-19-25-15-14(17(30)26-19)23-11(8-22-15)7-21-10-3-1-9(2-4-10)16(29)24-12(18(31)32)5-6-13(27)28/h1-4,8,12,21H,5-7H2,(H,24,29)(H,27,28)(H,31,32)(H3,20,22,25,26,30)/t12-/m0/s
Incafolic
KBio1_000494
KBio2_001861
KBio2_004429
KBio2_006997
KBio3_001558
KBioGR_002222
KBioSS_001861
Kyselina listova
Kyselina listova [Czech]
LS-2157
Liver Lactobacillus casei factor
MLS001304016
MLS001335861
Millafol
Mission prenatal
Mittafol
MolPort-004-285-551
N-(4-(((2-Amino-1,4-dihydro-4-oxo-6-pteridinyl)methyl)amino)benzo- yl)-L-glutamic acid
N-(4-((2-Amino-1,4-dihydro-4-oxo-6-pteridinyl)methyl)amino)benzoyl)-L-glutamic acid
N-(4-{[(2-Amino-4-oxo-3,4-dihydropteridin-6-yl)methyl]amino}benzoyl)-L-glutamic acid
N-(4-{[(2-amino-4-oxo-1,4-dihydropteridin-6-yl)methyl]amino}benzoyl)-L-glutamic acid
N-(p-(((2-Amino-4-hydroxy-6-pteridinyl)methyl)amino)benzoyl)-L-glutamic acid
N-Pteroyl-L-glutamic acid
N-[(4-{[(2-Amino-4-oxo-1,4-dihydropteridin-6-yl)methyl]amino}phenyl)carbonyl]-L-glutamic acid
N-[(4-{[(2-amino-4-oxo-1,4-dihydropteridin-6-yl)methyl]amino}phenyl)carbonyl]-L-glutamic acid
N-[4-[[(2-Amino-3,4-dihydro-4-oxo-6-pteridinyl)methyl]amino]benzoyl]-L-glutamic acid
NCGC00016265-01
NCGC00142391-01
NINDS_000494
NSC 3073
Nifolin
Nifolin [Denmark]
Novofolacid
Novofolacid [Canada]
PGA
PGA (VAN)
Prestwick3_000627
Prestwick_230
PteGlu
Pteroyl-L-glutamate
Pteroyl-L-glutamic acid
Pteroyl-L-monoglutamate
Pteroyl-L-monoglutamic acid
Pteroylglutamate
Pteroylglutamic acid
Pteroylmonoglutamate
Pteroylmonoglutamic acid
SAM002264616
SDCCGMLS-0066738.P001
SMP2_000137
SMR000471860
SPBio_001357
SPECTRUM1502020
Serum Folate Level
Spectrum2_001459
Spectrum3_000749
Spectrum4_001751
Spectrum5_000602
Spectrum_001381
UNII-935E97BOY8
Usaf cb-13
Vitamin B11
Vitamin B9
Vitamin Bc
Vitamin Be
Vitamin M
bmse000299
folic acid
nchembio.108-comp10
27Complement System ProteinsPhase 2232
28Protective AgentsPhase 27443
29Thioctic AcidPhase 2118
30MicronutrientsPhase 26001
31Vitamin B ComplexPhase 24337
32VitaminsPhase 25282
33Trace ElementsPhase 26001
34Adjuvants, ImmunologicPhase 22554
35Interferon-betaPhase 2284
36Antiviral AgentsPhase 29967
37interferonsPhase 22175
38Anti-Infective AgentsPhase 222062
39AntioxidantsPhase 23050
40Alpha-lipoic AcidNutraceuticalPhase 2118
41Vitamin B9NutraceuticalPhase 24392
42FolateNutraceuticalPhase 24392
43Chelating Agents1423
44Vaccines6611
45Calcium, Dietary5713
46Anticoagulants2623
47Antibodies, Anti-Idiotypic18
48
Citric Acidnutraceutical, vet_approved116077-92-9311
Synonyms:
2-Hydroxy-1,2,3-propanetricarboxylate
2-Hydroxy-1,2,3-propanetricarboxylic acid
2-Hydroxytricarballylic acid
3-Carboxy-3-hydroxypentane-1,5-dioate
3-Carboxy-3-hydroxypentane-1,5-dioic acid
Aciletten
Anhydrous citrate
Anhydrous citric acid
Chemfill
Citraclean
 
Citrate
Citretten
Citric acid
Citro
Citronensäure
E 330
Hydrocerol A
Kyselina citronova
Suby G
Uro-trainer
beta-Hydroxytricarballylate
beta-Hydroxytricarballylic acid
49CitrateNutraceutical1160

Interventional clinical trials:

(show top 50)    (show all 62)
idNameStatusNCT IDPhase
1IVIg for Demyelination in Diabetes MellitusRecruitingNCT02372149Phase 4
2Alemtuzumab in Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIPD)WithdrawnNCT01757574Phase 4
3Evaluate Efficacy and Safety of Fingolimod 0.5 mg Orally Once Daily Versus Placebo in Chronic Inflammatory Demyelinating Polyradiculoneuropathy Patients.CompletedNCT01625182Phase 3
4Phase III Randomized, Double-Blind, Placebo-Controlled Study of 3,4-Diaminopyridine for Demyelinating PolyneuropathyCompletedNCT00004939Phase 3
5Phase III Multicenter Double Blind Controlled Trial of Human Immune Globulin Therapy in Previously Untreated Patients With Chronic Inflammatory Demyelinating NeuropathyCompletedNCT00004286Phase 3
6Phase III Randomized, Double-Blind, Placebo-Controlled Study of Intravenous Immune Globulin for Chronic Inflammatory Demyelinating PolyneuropathyCompletedNCT00004772Phase 3
7Immune Globulin Intravenous (IGIV) For Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)CompletedNCT00220740Phase 3
8Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and Treatment With Subcutaneous Immunoglobulin (IgPro20)CompletedNCT01545076Phase 3
9Phase III Clinical Trial of NPB-01maintenance Therapy in Patients With Chronic Inflammatory Demyelinating Polyneuropathy.CompletedNCT01824251Phase 3
10Randomized Open-label Trial to Compare Efficacy and Tolerance of Corticosteroids and IVIgCompletedNCT01349270Phase 3
11Study of Efficacy and Safety of Privigen in Subjects With Chronic Inflammatory Demyelinating PolyneuropathyCompletedNCT01184846Phase 3
12Efficacy and Safety Study of GB-0998 for Guillain-Barré SyndromeCompletedNCT02342184Phase 3
13Phase III Clinical Trial of NPB-01 in Patients With Guillain-Barré SyndromeCompletedNCT02221271Phase 3
14Long-Term Tolerability and Safety of HYQVIA/HyQvia in CIDPRecruitingNCT02955355Phase 3
15Phase III Efficacy, Safety, and Tolerability Study of HYQVIA/HyQvia and GAMMAGARD LIQUID/KIOVIG in CIDPRecruitingNCT02549170Phase 3
16Efficacy and Safety Study of I10E in Treatment of Patients With CIDPRecruitingNCT02293460Phase 3
17Efficacy and Safety Study of I10E in the Maintenance Treatment of Patients With CIDP: Extension of PRISM Study I10E-1302RecruitingNCT02317562Phase 3
18Extension Study of Maintenance Treatment With Subcutaneous Immunoglobulin (IgPro20) for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)Active, not recruitingNCT02027701Phase 3
19Interest of Mycophenolate for CIDP WeaningActive, not recruitingNCT02494505Phase 3
20Panzyga in CIDP Administered at Different Infusion RatesNot yet recruitingNCT03166527Phase 3
21Safety and Efficacy Study of Three Different Dosages of NewGam in Patients With CIDPTerminatedNCT01225276Phase 2, Phase 3
22Inhibition of Complement Activation (Eculizumab) in Guillain-Barre Syndrome StudyUnknown statusNCT02029378Phase 2
23Subcutaneous Immunoglobulin Treatment of Patients With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)CompletedNCT01017159Phase 2
24Safety and Efficacy of Avonex in Subjects With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)CompletedNCT00099489Phase 2
25Lipoic Acid to Treat Chronic Inflammatory Demyelinating PolyneuropathyCompletedNCT00962429Phase 2
26Intravenous Immunoglobulin (IVIg) for the Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)CompletedNCT00001287Phase 2
27Assessment of Chronic Guillain-Barre Syndrome Improvement With Use of 4-aminopyridineCompletedNCT00056810Phase 2
28Early Mechanical Ventilation for Guillain Barré SyndromeCompletedNCT00167622Phase 2
29SERENDEM : MD1003 in Patients Suffering From Demyelinating Neuropathies, an Open Label Pilot StudyRecruitingNCT02967679Phase 1, Phase 2
30Small Volume Plasma Exchange (SVPE) for Guillain-Barré Syndrome (GBS) PatientsRecruitingNCT02780570Phase 2
31Hematopoietic Stem Cell Transplantation in Chronic Inflammatory Demyelinating PolyneuropathyActive, not recruitingNCT00278629Phase 2
32Pilot Study of Acthar® Gel in Chronic Inflammatory Demyelinating NeuropathyWithdrawnNCT02574962Phase 2
33High-dose Cyclophosphamide for Moderate to Severe Refractory Chronic Inflammatory Demyelinating PolyneuropathyWithdrawnNCT01236456Phase 2
34Prevalence of Decreased Corneal Sensation in Patients With Chronic Inflammatory Demyelinating PolyneuropathyUnknown statusNCT01379833
35Perception and Multisensory Integration in Neurological Patients Using fMRIUnknown statusNCT01469858
36Change of Nerve Conduction Properties in IVIg Dependent NeuropathiesUnknown statusNCT01655394
37The Changes of Cytokines in Guillain Barré Syndrome: the Correlation With Clinical Manifestations and Skin InnervationUnknown statusNCT00173199
38Study of CIDP Patients During IVIG TreatmentCompletedNCT00305266
39MRI in Diagnosing and Monitoring CIDPCompletedNCT02017769
40Effect of Resistance and Aerobic Exercise in CIDP or MMNCompletedNCT02121678
41Immunoglobulin Dosage and Administration Form in CIDP and MMNCompletedNCT02111590
42Magnetic Resonance Diagnostics of Diabetic Peripheral NeuropathyCompletedNCT01847937
43Effects of Robotic-assisted Gait Training In Non-Ambulatory Patients After Guillain-Barré SyndromeCompletedNCT02883270
44Regional Citrate Anticoagulation in Plasma Exchange TreatmentCompletedNCT01370200
45Intravenous Immunoglobulin (IVIG) Versus Plasma Exchange (PE) for Ventilated Children With Guillain Barre Syndrome (GBS)CompletedNCT01306578
46Safety Study of GBS Following Menactra Meningococcal VaccinationCompletedNCT00575653
47Brain Computer Interface for Communication in ICU: a Feasibility StudyCompletedNCT01005524
48Peristeen Bowel Irrigation System in Cauda EquinaCompletedNCT01784328
49Prospective Study on Swallowing/Breathing Interactions in Severe Guillain Barre Syndrome.CompletedNCT01024088
50Biomark Study: Predict Intravenous Immunoglobulin Responders in Chronic Inflammatory Demyelinating PolyradiculoneuropathyRecruitingNCT02629796

Search NIH Clinical Center for Polyradiculoneuropathy


Cochrane evidence based reviews: polyradiculoneuropathy

Genetic Tests for Polyradiculoneuropathy

About this section

Anatomical Context for Polyradiculoneuropathy

About this section

MalaCards organs/tissues related to Polyradiculoneuropathy:

36
T cells, Spinal cord, Brain, Thyroid, Tongue, Kidney, Skin

Publications for Polyradiculoneuropathy

About this section

Articles related to Polyradiculoneuropathy:

(show top 50)    (show all 496)
idTitleAuthorsYear
1
Treatments for chronic inflammatory demyelinating polyradiculoneuropathy (CIDP): an overview of systematic reviews. (28084646)
2017
2
Intravenous Immunoglobulins Lower Inflammatory Gene Expression in Skin Biopsies of Chronic Inflammatory Demyelinating Polyradiculoneuropathy Patients. (27286956)
2016
3
Human Endogenous Retrovirus and Neuroinflammation in Chronic Inflammatory Demyelinating Polyradiculoneuropathy. (27211560)
2016
4
A case of chronic inflammatory demyelinating polyradiculoneuropathy after treatment with pegylated interferon I+-2a in a patient with chronic hepatitis B virus infection. (27680223)
2016
5
Fatigue, Pain, Anxiety and Depression in Guillain-BarrAc Syndrome and Chronic Inflammatory Demyelinating Polyradiculoneuropathy. (27077919)
2016
6
Acute inflammatory demyelinating polyradiculoneuropathy in a newborn infant. (27238765)
2016
7
A case of a 17-year-old male with neurofascin-155 antibody-positive chronic inflammatory demyelinating polyradiculoneuropathy presenting with tremor and ataxia. (27580761)
2016
8
Chronic inflammatory demyelinating polyradiculoneuropathy: A new animal model for new therapeutic targets. (27838091)
2016
9
Stance Postural Strategies in Patients with Chronic Inflammatory Demyelinating Polyradiculoneuropathy. (26977594)
2016
10
Cerebral infarction following subcutaneous immunoglobulin therapy for chronic inflammatory demyelinating polyradiculoneuropathy. (26873805)
2016
11
A Bodybuilder With Weak Hands and Feet: Corticosteroid-Responsive Pure Motor Chronic Inflammatory Demyelinating Polyradiculoneuropathy Following Anabolic Steroid Use. (27438336)
2016
12
IgG4 anti-neurofascin155 antibodies in chronic inflammatory demyelinating polyradiculoneuropathy: Clinical significance and diagnostic utility of a conventional assay. (27852440)
2016
13
Evolution of hepatitis E virus-associated meningo-polyradiculoneuropathy on ribavirin. (27470489)
2016
14
Motor unit number index (MUNIX): Is it relevant in chronic inflammatory demyelinating polyradiculoneuropathy (CIDP)? (26750580)
2016
15
Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP): Clinical Features, Diagnosis, and Current Treatment Strategies. (27902997)
2016
16
Economic Evaluation of Intravenous Immunoglobulin plus Corticosteroids for the Treatment of Steroid-Resistant Chronic Inflammatory Demyelinating Polyradiculoneuropathy in Thailand. (27113227)
2016
17
Giant nerves in chronic inflammatory polyradiculoneuropathy. (27463360)
2016
18
Peripheral Nerve Ultrasonography in Chronic Inflammatory Demyelinating Polyradiculoneuropathy and Multifocal Motor Neuropathy: Correlations with Clinical and Neurophysiological Data. (27313890)
2016
19
Immunomodulation of inflammatory leukocyte markers during intravenous immunoglobulin treatment associated with clinical efficacy in chronic inflammatory demyelinating polyradiculoneuropathy. (27781132)
2016
20
Intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyradiculoneuropathy, a time to start and a time to stop. (27241239)
2016
21
Improving the management of chronic inflammatory demyelinating polyradiculoneuropathy. (27230584)
2016
22
Nivolumab-induced chronic inflammatory demyelinating polyradiculoneuropathy mimicking rapid-onset Guillain-BarrAc syndrome: a case report. (27380808)
2016
23
Transcriptome Analysis of Peripheral Blood in Chronic Inflammatory Demyelinating Polyradiculoneuropathy Patients Identifies TNFR1 and TLR Pathways in the IVIg Response. (27175635)
2016
24
A case of severe chronic inflammatory demyelinating polyradiculoneuropathy with monoclonal gammopathy of undetermined significance with alternating immunoglobulin class to IgM from IgA. (27580763)
2016
25
Multiple Myeloma Associated Chronic Inflammatory Demyelinating Polyradiculoneuropathy: The Importance of Continued Surveillance. (28070468)
2016
26
Pembrolizumab-Induced Demyelinating Polyradiculoneuropathy. (27468083)
2016
27
Triple-stimulation technique improves the diagnosis of chronic inflammatory demyelinating polyradiculoneuropathy. (25571892)
2015
28
Relapse with Dysphagia in a Case of Chronic Inflammatory Demyelinating Polyradiculoneuropathy. (26179538)
2015
29
Chronic inflammatory demyelinating polyradiculoneuropathy: from pathology to phenotype. (25677463)
2015
30
Plasma exchange for chronic inflammatory demyelinating polyradiculoneuropathy. (26305459)
2015
31
Steroids for chronic inflammatory demyelinating polyradiculoneuropathy: evidence base and clinical practice. (26437234)
2015
32
Which criteria for research in chronic inflammatory demyelinating polyradiculoneuropathy? an analysis of current practice. (25354388)
2015
33
Pupils in Acute Inflammatory Demyelinating Polyradiculoneuropathy Different From Adies Pupils. (26153043)
2015
34
Diagnosis of atypical forms of chronic inflammatory demyelinating polyradiculoneuropathy: a practical overview based on some case studies. (26392214)
2015
35
The diagnostic value of MRI in pediatric chronic inflammatory demyelinating polyradiculoneuropathy. (25972306)
2015
36
Chronic inflammatory demyelinating polyradiculoneuropathy with cranial nerves hypertrophy, thyroid-related orbitopathy and IgG monoclonal gammopathy: a case report. (25647292)
2015
37
Acute myeloid leucaemia presenting as a rapidly progressive polyradiculoneuropathy. (26581698)
2015
38
Chronic inflammatory demyelinating polyradiculoneuropathy with cholesterol deposits in a dog. (26450833)
2015
39
New insights into the management of chronic inflammatory demyelinating polyradiculoneuropathy. (26107324)
2015
40
Severe acute inflammatory demyelinating polyradiculoneuropathy with persistent weakness associated with tumor-like nerve root enlargement. (25996968)
2015
41
Long-term Immunoglobulin therapy for chronic inflammatory demyelinating polyradiculoneuropathy. (25556954)
2015
42
Update on the treatment of chronic inflammatory demyelinating polyradiculoneuropathy. (26203970)
2015
43
The frequencies of Killer immunoglobulin-like receptors and their HLA ligands in chronic inflammatory demyelinating polyradiculoneuropathy are similar to those in Guillian Barre syndrome but differ from those of controls, suggesting a role for NK cells in pathogenesis. (26198918)
2015
44
Corticosteroids for chronic inflammatory demyelinating polyradiculoneuropathy. (25561247)
2015
45
Primary Neurolymphomatosis Presenting With Polyradiculoneuropathy Affecting One Lower Limb. (26301373)
2015
46
Characteristic MRI features of chronic inflammatory demyelinating polyradiculoneuropathy. (25687202)
2015
47
Maintenace therapy in chronic inflammatory demyelinating polyradiculoneuropathy. (26088325)
2015
48
Leukodystrophy presenting as acute-onset polyradiculoneuropathy. (24685010)
2014
49
Severity and patterns of blood-nerve barrier breakdown in patients with chronic inflammatory demyelinating polyradiculoneuropathy: correlations with clinical subtypes. (25105500)
2014
50
Intravenous immunoglobulin response in treatment-naA^ve chronic inflammatory demyelinating polyradiculoneuropathy. (25515502)
2014

Variations for Polyradiculoneuropathy

About this section

Expression for genes affiliated with Polyradiculoneuropathy

About this section
Search GEO for disease gene expression data for Polyradiculoneuropathy.

Pathways for genes affiliated with Polyradiculoneuropathy

About this section

Pathways related to Polyradiculoneuropathy according to GeneCards Suite gene sharing:

(show all 27)
idSuper pathwaysScoreTop Affiliating Genes
19.7MBP, MPZ, PMP22
2
Show member pathways
9.4IFNG, IL17A, STAT3
39.4IL10, IL17A, STAT3
4
Show member pathways
9.4IFNG, PRF1, STAT3
59.3IFNG, IL17A, TBX21
69.3IFNB1, IFNG, IL10
79.3IFNB1, IFNG, IL10
8
Show member pathways
9.2IFNG, STAT3, TBX21
99.2ALB, CXCR4, STAT3
109.1CCL5, IFNB1
11
Show member pathways
9.1IFNG, IL10, IL17A, STAT3
129.1CXCR4, IL10, STAT3
139.0CCL5, IFNG, IL17A
149.0IFNG, IL10, IL17A, TBX21
15
Show member pathways
9.0IFNB1, IFNG, IL10, IL17A
168.9CCL5, IL10, STAT3
17
Show member pathways
8.9IFNB1, IFNG, IL10, STAT3
188.9IFNG, PRF1, STAT3, TBX21
19
Show member pathways
8.6IFNG, IL10, IL17A, STAT3, TBX21
20
Show member pathways
8.6IFNG, IL10, IL17A, STAT3, TBX21
21
Show member pathways
8.5CXCR4, IFNG, IL10, IL17A, PRF1
228.3CXCR4, IFNB1, IFNG, IL10, STAT3
23
Show member pathways
8.1CCL5, IFNB1, IFNG, IL10, STAT3
24
Show member pathways
7.8CCL5, IFNB1, IFNG, IL10, IL17A, STAT3
257.1CCL5, CXCR4, IFNG, IL10, IL17A, STAT3
26
Show member pathways
7.1CCL5, CXCR4, IFNB1, IFNG, IL10, IL17A
27
Show member pathways
7.1CCL5, CXCR4, IFNB1, IFNG, IL10, IL17A

GO Terms for genes affiliated with Polyradiculoneuropathy

About this section

Cellular components related to Polyradiculoneuropathy according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1myelin sheathGO:00432099.2ALB, MBP, MPZ, PMP2

Biological processes related to Polyradiculoneuropathy according to GeneCards Suite gene sharing:

(show all 18)
idNameGO IDScoreTop Affiliating Genes
1defense response to protozoanGO:004283210.6IFNG, IL10
2positive regulation of interleukin-6 secretionGO:200077810.5IL17A, MBP
3negative regulation of heterotypic cell-cell adhesionGO:003411510.5IL10, MBP
4positive regulation of interleukin-23 productionGO:003274710.4IFNG, IL17A
5negative regulation of growth of symbiont in hostGO:004413010.4IFNG, IL10
6positive regulation of osteoclast differentiationGO:004567210.4IFNG, IL17A
7positive regulation of MHC class II biosynthetic processGO:004534810.4IFNG, IL10
8myelinationGO:004255210.4MBP, MPZ, PMP22
9positive regulation of killing of cells of other organismGO:005171210.4IFNG, PRF1
10positive regulation of metalloendopeptidase activityGO:190468510.4MBP, STAT3
11positive regulation of isotype switching to IgG isotypesGO:004830410.2IFNG, TBX21
12positive regulation of peptidyl-serine phosphorylation of STAT proteinGO:003314110.2IFNB1, IFNG
13negative regulation of cell proliferationGO:00082859.8IFNG, IL10, PMP22, STAT3
14dendritic cell chemotaxisGO:00024079.8CCL5, CXCR4
15positive regulation of innate immune responseGO:00450899.7CCL5, IFNB1
16immune responseGO:00069559.1CCL5, IFNG, IL10, IL17A, MBP
17inflammatory responseGO:00069548.6CCL5, CXCR4, IL10, IL17A, STAT3
18response to virusGO:00096157.7CCL5, CXCR4, IFNB1, IFNG, TBX21

Molecular functions related to Polyradiculoneuropathy according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1CCR5 chemokine receptor bindingGO:00317309.8CCL5, STAT3
2fatty acid bindingGO:00055049.7ALB, PMP2
3cytokine activityGO:00051258.5CCL5, IFNB1, IFNG, IL10, IL17A

Sources for Polyradiculoneuropathy

About this section
2CDC
6CNVD
10DGIdb
15ExPASy
16FDA
17FMA
27GTR
28HGMD
29HMDB
30ICD10
31ICD10 via Orphanet
32ICD9CM
33IUPHAR
34KEGG
37MedGen
39MeSH
40MESH via Orphanet
41MGI
44NCI
45NCIt
46NDF-RT
49NINDS
50Novoseek
52OMIM
53OMIM via Orphanet
57PubMed
58QIAGEN
63SNOMED-CT via Orphanet
67Tumor Gene Family of Databases
68UMLS
69UMLS via Orphanet